ALKERMES
LIVE

Serial Number

88788969

Owner

Alkermes, Inc.

Attorney

Norm J. Rich

First Use Date

Jan 21, 2022

Filing Date

Feb 7, 2020

Add to watchlist:

No watchlists yet
View on USPTO

ALKERMES Trademark

Serial Number: 88788969 • Registration: 6925355

ALKERMES is a trademark filed by Alkermes, Inc. on February 7, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 36 (Insurance & Financial), Class 44 (Medical Services), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Alkermes, Inc.

852 Winter Street
Waltham, MA 024511420

Entity Type: 03

Trademark Details

Filing Date

February 7, 2020

Registration Date

December 13, 2022

First Use Anywhere

January 21, 2022

First Use in Commerce

January 21, 2022

Published for Opposition

September 22, 2020

Goods & Services

Providing grants to organizations dedicated to patient focused medical research; funding service awards, namely, providing grants to patient advocacy groups and institutions for the treatment and management of diseases including, but not limited to, addiction and central nervous system disorders; Providing insurance information about pharmacies, namely, providing a database featuring information about insurance coverage for pharmaceuticals in the nature of pharmacy selection based on patient health plan coverage requirements; providing insurance information about pharmaceutical coverage by patient health plans; providing insurance administration information to patients and health care providers about medication reimbursement options; insurance services, namely, insurance eligibility review and verification being support services for patients and for health care providers on behalf of their patients, namely, providing health benefit verification services to determine coverage of medication treatment in the health industry; financial administration of medication reimbursement programs being support services for patients and for health care providers on behalf of their patients, namely, coordinating medication reimbursement programs

Providing educational information in the field of medication treatment to health care providers and patients; providing educational information about pharmaceutical products relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals

Support services for health care providers and their patients in the nature of providing patient advocate and case management services, namely, coordinating the procurement of medication in the nature of coordinating with pharmacies to facilitate prescription fulfillment; providing patient advocate and case management services in the nature of support services for patients and for health care providers on behalf of their patients, namely, coordinating the procurement and administration of medication in the nature of locating health care providers that can prescribe and/or administer prescribed medication

Administration and management of an annual competitive award program in the nature of research grants for scientific research; Logistics management in the field of medication, namely, business services in the nature of supporting the coordination of medication delivery to avoid product delivery delays; providing business administration information to patients and health care providers about medication reimbursement options regarding reimbursement procedures; providing information about pharmaceutical services, namely, providing information about processing online prescription orders in retail pharmacies regarding pharmacy authorization in the nature of prescription fulfillment and approval instructions for delivery of medication in the nature of accepting payment terms; appointment reminder services being support services for patients and for health care providers on behalf of their patients

Pharmaceutical preparations, namely, compounds for use in treating addiction, substance abuse and dependence, diseases and disorders of the central nervous system, cancer, reward disorders, psychiatric and neurodegenerative diseases and disorders in the nature of schizophrenia, depression, major depressive disorder, stress, anxiety, treatment resistant depression, bipolar depression, and bipolar disorder; pharmaceutical preparations for use in treating cardiovascular diseases and metabolic diseases; pharmaceutical preparations for the mitigation of weight gain and the treatment of metabolic diseases and dyslipidaemia; Pharmaceutical preparations, namely, prodrugs and chemical derivatives of pharmaceutically active ingredients for the treatment of central nervous system diseases and disorders, psychiatric and neurodegenerative diseases, cardiovascular diseases and metabolic diseases; pharmaceutical preparations in the nature of compounds, namely, small molecules and chemical compounds for use in opioid modulation for treating opioid use disorders

Filing History

ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Apr 24, 2026 ASCK
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 13, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 13, 2022 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Nov 9, 2022 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Nov 8, 2022 CNPR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 8, 2022 EXRA
STATEMENT OF USE PROCESSING COMPLETE
Nov 7, 2022 SUPC
SOU EXTENSION 4 GRANTED
Nov 7, 2022 EX4G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 7, 2022 AITU
USE AMENDMENT FILED
Oct 28, 2022 IUAF
SOU EXTENSION 4 FILED
Oct 28, 2022 EXT4
SOU TEAS EXTENSION RECEIVED
Oct 28, 2022 EEXT
TEAS STATEMENT OF USE RECEIVED
Oct 28, 2022 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 7, 2022 EXRA
SOU EXTENSION 3 GRANTED
May 5, 2022 EX3G
SOU EXTENSION 3 FILED
May 5, 2022 EXT3
SOU TEAS EXTENSION RECEIVED
May 5, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 18, 2021 EXRA
SOU EXTENSION 2 GRANTED
Nov 16, 2021 EX2G
SOU EXTENSION 2 FILED
Nov 16, 2021 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 16, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 1, 2021 EXRA
SOU EXTENSION 1 GRANTED
Apr 29, 2021 EX1G
SOU EXTENSION 1 FILED
Apr 29, 2021 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 29, 2021 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 17, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 22, 2020 NPUB
PUBLISHED FOR OPPOSITION
Sep 22, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 2, 2020 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 17, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 7, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 6, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 6, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 28, 2020 GNRN
NON-FINAL ACTION E-MAILED
Apr 28, 2020 GNRT
NON-FINAL ACTION WRITTEN
Apr 28, 2020 CNRT
ASSIGNED TO EXAMINER
Apr 28, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 11, 2020 NWOS
NEW APPLICATION ENTERED
Feb 11, 2020 NWAP